Comparação entre o uso tópico do fumarato de cetotifeno 0,025% e do cloridrato de olopatadina 0,1% no tratamento da ceratoconjuntivite primaveril

Hida, Wilson Takashi; Nogueira, Daniel Cruz; Schaefer, A. R.; Dantas, Paulo E.C.; Dantas, Maria Cristina Nishiwaki

doi:10.1590/s0004-27492006000600013

Cited by 14 publications

(4 citation statements)

References 17 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both have been shown to improve the signs and symptoms of VKC, and there is evidence that ketotifen may be more effective. 16 Some antihistamines may have a drying effect, which could exacerbate symptoms.…”

Section: Treatmentmentioning

confidence: 99%

Vernal keratoconjunctivitis

Addis¹,

Jeng²

2018

OPTH

View full text Add to dashboard Cite

Vernal keratoconjunctivitis (VKC) is a chronic allergic conjunctivitis that is most often seen in young, males. Although most types of allergic conjunctivitis do not affect vision, VKC is unusual in that damage to the cornea from the condition can result in vision loss. Although it is typically seasonal, year-round symptoms can be seen, which can lead to uncertain diagnoses being made. Although the pathophysiology of VKC is better understood in recent years, allowing more targeted therapies, management of these patients can still be very challenging, and complications can occur. As such, aggressive management of VKC is necessary, especially since vision loss in the amblyogenic age range can be permanent.

show abstract

Section: Treatmentmentioning

confidence: 99%

Vernal keratoconjunctivitis

Addis¹,

Jeng²

2018

OPTH

View full text Add to dashboard Cite

show abstract

“…These two drugs may have also anti-inflammatory properties, reducing eosinophil activation and cytokine release. A significant difference in favor of ketotifen-treated patients has being shown in a single-center, simple-masked study comparing these two drugs [29]. However, both drugs were efficient and safe relieving the main symptoms and signs of VKC, including itching, tearing, conjunctival hyperemia, mucous discharge and photophobia.…”

Section: Management Of Vkcmentioning

confidence: 99%

Management of Vernal Keratoconjunctivitis

Leonardi

2013

Ophthalmol Ther

130

View full text Add to dashboard Cite

Vernal keratoconjunctivitis (VKC) is a relatively rare, chronic form of ocular allergy that can potentially cause severe visual complications. Affecting mainly children and young adults, it is an IgE- and T cell-mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte and structural cell activation are involved. Treatment of VKC requires a multiple approach that includes conservative measures and pharmacologic treatment. Patients and parents should be made aware of the long duration of disease, its chronic evolution and possible complications. Treatment should be based on the duration and frequency of symptoms and the severity of corneal involvement. Mast cell stabilizers and antihistamines have been proven to be effective for the treatment of mild to moderate forms of VKC. In the most severe cases, topical steroids can be used as rescue medication to reduce conjunctival and corneal inflammation. Immunomodulators that have been investigated for VKC treatment include topical ocular preparations of cyclosporine A and tacrolimus. Topical cyclosporine A has been proven to be effective in the long-term treatment of VKC, significantly improving signs and symptoms without significant side effects.

show abstract

“…These include alcaftadine, azelastine 0.05%), bepotastine besilate (1.5%), epinastine (0.05%), ketotifen (0.025%), and olopatadine (0.1%, 0.2%). [ 19 ] In our survey, dual-acting agents (40%) and mast cell stabilizers (31.1%) were commonly prescribed in mild-moderate cases of allergy. When enquired about dosing of olopatadine, 0.1% twice-daily dosing was preferred by 33%.…”

Section: Discussionmentioning

confidence: 95%

Practice patterns and opinions in the treatment of allergic eye disease: A survey among Indian ophthalmologists

Priyadarshini

Das

2023

Indian J Ophthalmol

View full text Add to dashboard Cite

Purpose: Management of allergic eye disease is seldom straightforward and often challenging. We conducted an online survey to elicit opinions on the preferred practice pattern in the treatment of allergic eye disease. Methods: An online survey questionnaire was sent to all practicing ophthalmologists using social media platforms. The respondents were asked about their clinical experience and preferred treatment in various scenarios such as mild-moderate vernal keratoconjunctivitis (VKC), chronic VKC, refractory VKC, steroid responders, giant papillae, and shield ulcer. Respondents were asked about the newer molecule (alcaftadine) and reservations regarding systemic immuno-suppressants and ordering allergy tests in their practice. Results: Ninety - one participants responded to the survey. About 57.1% of ophthalmologists reported coming across more than 10 cases per week in their practice. The most common age group was 5–10 years (61.1%), but adult onset VKC was also reported at 41.6% (1–2 per month), 37.1% (3–5 per month), and 13.5% (more than 10 per month). The disease is perennially present (36.7%), and a mixed form has been reported by 47.8% of ophthalmologists. Dual-acting agents were preferred by 40% in mild-moderate clinical variants. Topical steroids in slow tapering dosage were preferred by 86.7% in their prescription. Tacrolimus 0.03% was preferred by 65.9% and given for at least 3 months of continuous usage by 47.6% of ophthalmologists. High-dose topical steroids were preferred for giant papillae (67.8%) and Shields ulcers (68.3%) in our survey. Supratarsal steroid injection was preferred by 50% in treating refractory VKC in our survey. Conclusion: Allergic eye disease is a common yet annoying disease. The signs and symptoms can vary from subtle, innocuous forms to devastating variants affecting vision and day-to-day work. This survey aims to elicit responses from clinicians spreading across different geographical areas and compares responses based on experience in practice.

show abstract

Comparação entre o uso tópico do fumarato de cetotifeno 0,025% e do cloridrato de olopatadina 0,1% no tratamento da ceratoconjuntivite primaveril

Cited by 14 publications

References 17 publications

Vernal keratoconjunctivitis

Vernal keratoconjunctivitis

Management of Vernal Keratoconjunctivitis

Practice patterns and opinions in the treatment of allergic eye disease: A survey among Indian ophthalmologists

Contact Info

Product

Resources

About